Justina Ramuokaite

Justina Ramoskaite is a finance and investing professional whose career spans investment banking, healthcare private equity, and operating leadership in health technology. Raised in Lithuania, she was reportedly the first student from her high school to attend university abroad; she earned an undergraduate degree from the University of Bath in the United Kingdom and later a self-funded MBA from Harvard Business School.

She began her finance career in investment banking at Jefferies, where her transaction experience included IPOs and large-scale M&A — most notably work associated with Novartis's acquisition of Advanced Accelerator Applications for over $3 billion. Around 2018 she joined G Square (G Square Healthcare Private Equity) in London as a Private Equity Associate, working on healthcare investments for the firm, which is the origin of the gsquarecapital.com contact record in this profile.

More recently, Ramoskaite crossed over from the deal side to the operating side of health-tech. She spent roughly three years at Freshpaint — a healthcare data-privacy/compliance software company — in a Finance and Operations leadership capacity (variously listed as Head of / VP Finance & Operations and Chief of Staff), where she led financial modeling for the company's ~$30M Series B round and supported investor due diligence, and helped scale the company from about 15 to 85+ employees. Public records also associate her with a finance/operations role at AllSpice; in all cases her focus is building the financial forecasting, compliance, and revenue-operations infrastructure that early- and growth-stage health-tech companies need.

Beyond her day job she is active in executive operator communities (Operators Guild, The F Suite), mentors women in finance, and coaches and adjudicates competitive debate.

• At G Square (firm thesis): control-oriented private equity in European mid-market healthcare, targeting companies with high growth potential across four segments — medical products, healthcare IT, healthcare services, and services to pharma. Typical equity checks of roughly €30M–€60M.
• Ramoskaite's personal expertise sits at the intersection of healthcare + finance operations — she evaluates companies through the lens of durable unit economics, forecastable growth, and governance/compliance readiness rather than early-stage moonshots.
• Her operating experience skews toward healthcare technology and data/privacy-compliance software (e.g., Freshpaint) — sectors where regulatory rigor and enterprise trust are core to the value proposition.
• She values structure that enables growth — forecasting systems, compliance protocols, and RevOps infrastructure — which is a strong signal of what she looks for in a business she'd back or help operate.